Month: August 2022

Second Quarter Revenue Increased 63.5% Year-Over-Year to $19.3 Million Company Takes Actions to Mitigate Industry Challenges and Better Position Itself for Sustainable Growth BILLERICA, Mass., Aug. 15, 2022 (GLOBE NEWSWIRE) — Agrify Corporation (Nasdaq:AGFY) (“Agrify” or the “Company”), a leading provider of innovative cultivation and extraction solutions for the cannabis industry, today announced financial results for the second quarter ended June 30, 2022. “The second quarter was challenging for the entire cannabis industry,” said Raymond Chang, Chairman and Chief Executive Officer of Agrify. “Despite this difficult business environment, which has impacted our recent performance and altered our outlook for the remainder of 2022, we are actively taking steps to adapt to the new market realities. We have adjusted...

– Generated positive cash flow from mining operations – – Mined 1,257 BTC in Q2 2022 and 500 BTC in July 2022 – – Increased capacity and production with new locations in Quebec – – Continued build out in Argentina and on track to start production in Q4 2022 – This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated August 16, 2021 to its short form base shelf prospectus dated August 12, 2021. TORONTO, Ontario and BROSSARD, Québec, Aug. 15, 2022 (GLOBE NEWSWIRE) — Bitfarms Ltd. (NASDAQ: BITF // TSX: BITF), a global Bitcoin self-mining company, reported its financial results for the second quarter ended June 30, 2022. All financial references are in U.S. dollars. During second quarter 2022, Bitfarms mined 1,257 bitcoin (BTC). “In...

VANCOUVER, British Columbia, Aug. 15, 2022 (GLOBE NEWSWIRE) — K92 Mining Inc. (“K92” or the “Company”) (TSX: KNT; OTCQX: KNTNF) is pleased to announce second quarter financial results for the three and six months ended June 30, 2022. SafetyStrong focus on safety with one of the best safety records in the Australasia region since commencement of operations. Proactive and focused management of COVID-19. K92 has continuously operated throughout the COVID-19 pandemic, and has strong preventative and response plans, with pandemic resiliency strengthening through ongoing vaccination programs.ProductionRecord plant throughput of 108,853 tonnes processed during the quarter, or 1,196 tonnes per day (“tpd”), significantly exceeding the Stage 2 Expansion run-rate and a 44% increase from Q2 2021. Record mine throughput with 114,471 tonnes...

Submitted IND for AK-OTOF to FDAContinued progress toward planned IND submission for AK-antiVEGFPresented new nonclinical data at ASGCT supporting the proposed clinical development of AK-OTOF and highlighting strategies for regulated gene expression in the inner earReceived a notice of allowance from USPTO for claims covering compositions, including AK-OTOF, and methods of treatment useful for OTOF-mediated hearing lossEnded Q2 2022 with a strong cash position of $192.9 millionBOSTON, Aug. 15, 2022 (GLOBE NEWSWIRE) — Akouos, Inc. (Nasdaq: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today reports financial results for the second quarter ended June 30, 2022 and provides business highlights. “We continue to...

All FREEDOM-1 patients who received FCR001 at least three months prior to the data cutoff date of June 15, 2022 had achieved and maintained >50% T-cell chimerism, and all three patients who were dosed at least 12 months post-transplant have discontinued their chronic anti-rejection drugs Multiple oral and poster presentations at the American Transplant Congress (ATC) 2022 highlighted key research findings and long-term Phase 2 follow up Strong cash balance with expected runway through 2024 BOSTON and LOUISVILLE, Ky., Aug. 15, 2022 (GLOBE NEWSWIRE) — Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today reported financial results for the three- and six-month...

Conference Call to Be Held Today at 10:00 am ET QUINCY, Mass., Aug. 15, 2022 (GLOBE NEWSWIRE) — Stran & Company, Inc. (“Stran” or the “Company”) (NASDAQ: STRN) (NASDAQ: STRNW), a leading outsourced marketing solutions provider that leverages its promotional products and loyalty incentive expertise, today provided a business update and reported financial results for the three months ended June 30, 2022. Andy Shape, President and CEO of Stran, commented, “We continued our growth trajectory during the second quarter, illustrated by record revenue of $14.8 million, a 72.5% increase compared to the same period last year. Importantly, on an organic basis, our year-over-year revenue increased 49.4%, reinforcing our traction in the market. We remain committed to our business growth strategy involving expansion...

London, UK, Aug. 15, 2022 (GLOBE NEWSWIRE) — Trading volumes reported by foreign exchange broker Iconic Management Services Limited, like its peers, managed to achieve month-on-month growth.The early months of 2022 witnessed low trading volumes across the industry amid weak global growth and the ongoing pandemic. In fact, trading volumes were down almost all of last year. However, many brokerages have reported month-on-month volume growth in July 2022. Iconic’s total trading volume for the month is 92.8 billion yen ($688 million), representing an increase of about 21.5% compared to that of the previous month. Although Iconic announced a month-in-month increase in trading volumes, there is no year-on-year increase. Compared with July 2021, the trading volume is about 13.6% lower. Iconic reported monthly deposits of 133.81 billion...

Presented updated clinical data from an investigator-initiated trial (IIT) evaluating FasTCAR GC012F for the treatment of relapsed/refractory multiple myeloma (r/r MM) at ASCO and EHA 2022, which underscored the deep response with a 100% MRD negativity rate Presented first-in-human data of GC012F in relapsed/refractory B-cell Non-Hodgkin’s lymphomas (r/r B-NHL) at EHA 2022 Presented updated results from an IIT evaluating allogeneic TruUCAR GC502 in relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) at EHA 2022 Continued enrollment in an IIT evaluating GC012F in newly diagnosed multiple myeloma (NDMM) patients Completed the Phase 1 portion of the registrational Phase 1/2 clinical trial under a China IND for GC007g in r/r B-ALL Strengthened leadership team with appointments of Dr. Wendy Li as Chief Medical Officer and Dr....

– Positive initial clinical data from ongoing Phase 1/2 Trial evaluating VRDN-001 in patients with Thyroid Eye Disease (TED) – – VRDN-002 achieved a substantially extended half-life of 30-40 days in healthy volunteers with a sustained IGF-1 response and a favorable safety and tolerability profile – – Ended 2Q 2022 with cash, cash equivalents and short-term investments of $161 million, in addition to $75M credit facility, provide cash runway into 2024 – Conference call today at 8:00 a.m. ET – WALTHAM, Mass., Aug. 15, 2022 (GLOBE NEWSWIRE) — Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases underserved by current therapies, today announced financial results for the second quarter ending June 30, 2022 and...